{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:18:48Z","timestamp":1763457528251},"reference-count":11,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.3892\/etm.2016.3439","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T11:51:03Z","timestamp":1465386663000},"page":"1177-1180","source":"Crossref","is-referenced-by-count":12,"title":["Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: A case report"],"prefix":"10.3892","volume":"12","author":[{"given":"Yanhua","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"key":"key20180108133349_b1-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/mhj.2000.107554","article-title":"Thrombocytopenia complicating treatment with intravenous glycoprotein IIb\/IIIa receptor inhibitors: A pooled analysis","volume":"140","author":"Dasgupta","year":"2000","journal-title":"Am Heart J"},{"key":"key20180108133349_b2-etm-0-0-3439","first-page":"33","article-title":"Newer agents in antiplatelet therapy: A review","volume":"3","author":"Yeung","year":"2012","journal-title":"J Blood Med"},{"key":"key20180108133349_b3-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0828-282X(07)70858-9","article-title":"Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb\/IIIa antagonists for percutaneous coronary intervention","volume":"23","author":"Labinaz","year":"2007","journal-title":"Can J Cardiol"},{"key":"key20180108133349_b4-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3892\/etm.2015.2830","article-title":"Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia","volume":"10","author":"Li","year":"2015","journal-title":"Exp Ther Med"},{"key":"key20180108133349_b5-etm-0-0-3439","first-page":"271","article-title":"New treatment options for primary immune thrombocytopenia","volume":"173","author":"Gudbrandsdottir","year":"2011","journal-title":"Ugeskr Laeger"},{"key":"key20180108133349_b6-etm-0-0-3439","first-page":"1793","article-title":"Report: Heparin-induced thrombocytopenia associated with cardiopulmonary bypass: Preliminary attempt with recombinant human thrombopoietin therapy","volume":"28","author":"Yuan","year":"2015","journal-title":"Pak J Pharm Sci"},{"key":"key20180108133349_b7-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2143\/AC.61.5.2017776","article-title":"Tirofiban-associated acute thrombocytopenia","volume":"61","author":"Tuhta","year":"2006","journal-title":"Acta Cardiol"},{"key":"key20180108133349_b8-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"key20180108133349_b9-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.amjcard.2005.08.066","article-title":"Frequency and management of thrombocytopenia with the glycoprotein IIb\/IIIa receptor antagonists","volume":"97","author":"Huxtable","year":"2006","journal-title":"Am J Cardiol"},{"key":"key20180108133349_b10-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1634\/theoncologist.1-1-98","article-title":"Thrombopoietin: Biology and clinical applications","volume":"1","author":"Kuter","year":"1996","journal-title":"Oncologist"},{"issue":"2 Suppl","key":"key20180108133349_b11-etm-0-0-3439","doi-asserted-by":"crossref","first-page":"53S","DOI":"10.1378\/chest.127.2_suppl.53S","article-title":"Immune thrombocytopenia caused by glycoprotein IIb\/IIIa inhibitors","volume":"127","author":"Aster","year":"2005","journal-title":"Chest"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2016.3439\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T21:52:59Z","timestamp":1600725179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2016.3439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6,8]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.3892\/etm.2016.3439"],"URL":"https:\/\/doi.org\/10.3892\/etm.2016.3439","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]}}}